Tuberculosis is an infectious disease of the lungs that’s been with humanity for centuries and affects a quarter of the world’s population. The stubborn disease killed over a million and a half people in 2021, mostly in lower- and middle- income countries where access to basic resources is scarce.

In treating diseases with drugs, dosing is critical; too little is ineffective, while too much can be lethal. Colorado State University’s Brad Reisfeld takes a mathematical approach to achieving optimal dosing for various drugs.

When results from a landmark tuberculosis vaccine trial in Cape Town, South Africa were published in The Lancet in February 2013, the headlines were grim, despite hopes that the trial would point toward a successful way to thwart one of the globe’s biggest public health threats.

Researchers at Colorado State University are launching the most realistic study ever conducted into how transmission of the tuberculosis pathogen triggers infectious disease, an investigation expected to yield new insights into a disease that attacks the lungs and kills some 1.5 million people worldwide each year.